Shares of Sutro Biopharma Inc (NASDAQ:STRO) have been assigned a consensus rating of “Buy” from the seven research firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $22.75.
STRO has been the subject of a number of recent research reports. Zacks Investment Research raised Sutro Biopharma from a “sell” rating to a “hold” rating in a report on Thursday, June 13th. Wedbush raised their price target on Sutro Biopharma from $20.00 to $22.00 and gave the company an “outperform” rating in a report on Monday, March 4th. HC Wainwright assumed coverage on Sutro Biopharma in a report on Monday, April 29th. They set a “buy” rating and a $18.00 price target for the company. Cowen reaffirmed a “buy” rating on shares of Sutro Biopharma in a report on Thursday, May 16th. Finally, ValuEngine cut Sutro Biopharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st.
Shares of STRO opened at $11.67 on Friday. Sutro Biopharma has a 1 year low of $8.50 and a 1 year high of $15.90. The stock has a 50 day moving average of $11.09.
A number of hedge funds have recently added to or reduced their stakes in STRO. American International Group Inc. acquired a new stake in Sutro Biopharma during the 4th quarter valued at $38,000. Deutsche Bank AG acquired a new stake in Sutro Biopharma during the 4th quarter valued at $87,000. Spark Investment Management LLC acquired a new stake in Sutro Biopharma during the 1st quarter valued at $168,000. SG Americas Securities LLC acquired a new stake in Sutro Biopharma during the 4th quarter valued at $169,000. Finally, Geode Capital Management LLC bought a new position in Sutro Biopharma in the 4th quarter valued at $456,000. 49.00% of the stock is owned by hedge funds and other institutional investors.
Sutro Biopharma Company Profile
Sutro Biopharma, Inc operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers.
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.